Switching from finasteride to dutasteride caused significant shedding but minimal side effects. The user plans to continue dutasteride for 12 months despite concerns about hair density.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
The user switched from finasteride to dutasteride 0.5 mg daily due to worsening hair loss and is seeking opinions on any noticeable regrowth or improvement. Some users suggest there might be more thick hairs, while others find it hard to compare due to different photo angles.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.
Combining finasteride with dutasteride may have additive benefits for reducing scalp DHT, but the extent is unknown. Some users report less shedding when using both treatments, with variations in dosage and application methods.
The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Pumpkin seed oil is a weak natural DHT inhibitor and not effective for significant hair loss. Effective treatments include finasteride, minoxidil, and other medications.
PP405 is still undergoing trials despite skepticism about its effectiveness. Some believe it shows potential for hair regrowth, possibly in combination with other treatments like minoxidil or finasteride, while others are doubtful due to past disappointments with similar products.
The user shared impressive hair regrowth results after 1.5 years using dutasteride (DUT) and oral minoxidil. They switched from finasteride and topical minoxidil due to lack of results and experienced no side effects.
The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.
A company is developing a topical dutasteride that targets hair follicles without significantly affecting systemic DHT levels, with trials underway to measure its effectiveness. Users discuss the potential benefits and skepticism around the formulation compared to existing treatments.
PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
Pumpkin seed oil and saw palmetto are discussed as natural DHT blockers with potentially fewer side effects than finasteride. Users share experiences with these treatments, noting concerns about mental health and side effects from finasteride.
The user reports significant hair regrowth after 200 days using dutasteride and minoxidil, attributing changes to hair dye. Others doubt the authenticity and discuss treatment effectiveness and side effects.
People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.
The conversation discusses hair loss treatment progress using Dutasteride for almost six months. Users debate its effectiveness compared to Finasteride and emphasize the importance of starting treatment early.
A user shared progress pictures after 5 months of using Dutasteride 0.5 mg and Minoxidil 2.5 mg, with a hair transplant planned for August 2027. Suggestions included increasing Minoxidil dosage and considering Finasteride if results are not satisfactory.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.